公开(公告)号：US12042561B2

公开(公告)日：2024-07-23

申请号：US16900978

申请日：2020-06-14

Applicant: ANP Technologies, Inc.

Inventor： Dujie Qin ,  Ray Yin ,  Jing Pan ,  Yubei Zhang

IPC: A61K9/14 ,  A61K9/19 ,  A61K9/51 ,  A61K31/337 ,  A61K31/4375 ,  A61K31/4745 ,  A61K33/243 ,  A61K45/06 ,  A61K47/34 ,  A61K47/58 ,  A61K47/59 ,  A61K47/68 ,  A61K49/00 ,  A61K49/12 ,  A61K51/06

CPC classification number: A61K9/14 ,  A61K9/19 ,  A61K9/513 ,  A61K9/5146 ,  A61K31/337 ,  A61K31/4375 ,  A61K31/4745 ,  A61K33/243 ,  A61K45/06 ,  A61K47/34 ,  A61K47/58 ,  A61K47/59 ,  A61K47/6803 ,  A61K49/0004 ,  A61K49/12 ,  A61K51/06

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

公开(公告)号：US20240238401A1

公开(公告)日：2024-07-18

申请号：US18561848

申请日：2022-05-23

Applicant: Takeda Vaccines, Inc.

Inventor： Tuhin BHOWMIK ,  Ke GONG ,  Zhengrong CUI ,  Robert O. WILLIAMS ,  Haiyue XU

IPC: A61K39/125 ,  A61J1/06 ,  A61K9/16 ,  A61K9/19 ,  A61K39/00

CPC classification number: A61K39/125 ,  A61K9/1623 ,  A61K9/19 ,  A61J1/065 ,  A61K2039/5258 ,  A61K2039/55505

Abstract: The present invention is directed to a solid composition comprising: antigen particles comprising virus like particles (VLPs) adsorbed on adjuvant particles.

公开(公告)号：US12036323B2

公开(公告)日：2024-07-16

申请号：US18215483

申请日：2023-06-28

Applicant: Adare Pharmaceuticals USA, Inc.

Inventor： Nathan Dormer ,  Cory Berkland

IPC: A61K9/16 ,  A61K9/00 ,  A61K9/19 ,  A61K31/00 ,  A61K45/06

CPC classification number: A61K9/1652 ,  A61K9/0019 ,  A61K9/1647 ,  A61K31/00 ,  A61K45/06 ,  A61K9/19

Abstract: Novel microsphere compositions for use in parenteral formulations are provided. The microspheres comprise a biodegradable polymer of a molecular weight greater than 10,000 daltons, an active therapeutic agent, and a cellulose-derived material such as ethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, or sodium carboxymethyl cellulose. The microsphere compositions decreased deviation in mean microsphere diameter, improved drug entrapment, and improved microsphere stability.

公开(公告)号：US12036252B2

公开(公告)日：2024-07-16

申请号：US18141821

申请日：2023-05-01

Applicant: Shayne Morris ,  Michael Benson

Inventor： Shayne Morris ,  Michael Benson

IPC: A61K35/742 ,  A61K9/19 ,  A61K35/744 ,  C12N1/20

CPC classification number: A61K35/742 ,  A61K9/19 ,  A61K35/744 ,  C12N1/20

Abstract: A method for growing probiotic organisms wherein the growth media includes prebiotics especially selected and prepared to be paired with the probiotic organisms being grown. The prebiotic formula is optimized to grow the desired probiotic organisms, as well as important byproducts of the growth process. Specialized freeze-drying buffers may also be paired with certain probiotic organisms for the freeze-drying process. Specific products may utilize selected probiotic organisms grown and supported with paired prebiotic formulas to promote and maintain physiological health in a subject.

公开(公告)号：US12036219B2

公开(公告)日：2024-07-16

申请号：US14775465

申请日：2014-03-14

Applicant: Melinta Subsidiary Corp.

Inventor： Erin M. Duffy

IPC: A61K31/4709 ,  A61K9/00 ,  A61K9/19 ,  A61K9/20 ,  A61K31/133 ,  A61K47/18 ,  A61K47/26 ,  A61K47/40

CPC classification number: A61K31/4709 ,  A61K9/0019 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/133 ,  A61K47/183 ,  A61K47/26 ,  A61K47/40 ,  A61K31/133 ,  A61K2300/00 ,  A61K31/4709 ,  A61K2300/00

Abstract: The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics. According to statistics compiled by National Health and Nutrition Examination Survey conducted by the National Center for Health Statistics (NCHS) of the U.S. Centers for Disease Control and Prevention (CDC), in 2009-2010, 35.7% of adults in the United States were found to be obese. Ogden, C.L. NCHS Data Brief 2012, 82, available at http://www.cdc.gov/nchs/data/databiefs/db82.pdf (last visited Mar. 2, 2013).

公开(公告)号：US20240228606A1

公开(公告)日：2024-07-11

申请号：US18612141

申请日：2024-03-21

Applicant: GENENTECH, INC.

Inventor： ChinYu LIN ,  Theodore A. OMACHI ,  Ryan P. OWEN ,  Karl YEN ,  Yanan ZHENG ,  Kendra DEBUSK

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/19 ,  A61K31/573 ,  A61K39/00 ,  A61K39/395 ,  A61P17/00

CPC classification number: C07K16/244 ,  A61K9/0014 ,  A61K9/0024 ,  A61K9/19 ,  A61K31/573 ,  A61K39/3955 ,  A61P17/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76

Abstract: Uses of IL-13 antagonists for treating atopic dermatitis are provided. Also provided are methods of treating atopic dermatitis and methods of reducing the severity of atopic dermatitis by administering IL-13 antagonists.

公开(公告)号：US20240208984A1

公开(公告)日：2024-06-27

申请号：US18552761

申请日：2022-03-30

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Yan ZHANG

IPC: C07D489/08 ,  A61K9/19 ,  A61K31/485 ,  A61K47/55 ,  G01N33/68

CPC classification number: C07D489/08 ,  A61K9/19 ,  A61K31/485 ,  A61K47/55 ,  G01N33/6863

Abstract: Bivalent ligands which bind to MOR-CCR5 heterodimers are provided. The bivalent ligands comprise two discrete pharmacophores, naltrexone and maraviroc, linked by a spacer and bind to MOR-CCR5 heterodimers, e.g. at the surface of a cell. The bivalent ligands are useful in assays to detect MOR-CCR5 heterodimers, as therapeutic agents to prevent and/or treat diseases characterized by the presence of MOR-CCR5 heterodimers.

公开(公告)号：US12016903B2

公开(公告)日：2024-06-25

申请号：US15528350

申请日：2015-11-20

Applicant: Ascendis Pharma Endocrinology Division A/S

Inventor： Kennett Sprogøe ,  Henrik Egesborg ,  Steen Jensen ,  Thomas Kurpiers

IPC: A61K38/27 ,  A61K9/00 ,  A61K9/19 ,  A61K47/60 ,  A61M5/19

CPC classification number: A61K38/27 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/60 ,  A61M5/19

Abstract: The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, to a multitude of unit dosage forms comprising a long-acting growth hormone formulation, wherein the unit dosage forms comprise increasing amounts of growth hormone equivalents and wherein the amount of growth hormone equivalents increases by at least 10% between one unit dosage form and the next higher dosage form; their use in a method of treating growth hormone deficiency and method of treating growth hormone deficiency in a bracketed dosing regimen.

公开(公告)号：US11993634B2

公开(公告)日：2024-05-28

申请号：US17422835

申请日：2020-05-14

Applicant: BEIJING LUZHU BIOTECHNOLOGY CO., LTD.

Inventor： Jian Kong ,  Pei Hong Jiang ,  Ling Peng ,  Shuai Yang ,  Leitao Xu ,  Kun Zhang

IPC: C07K14/005 ,  A61K9/19 ,  A61K39/25 ,  A61K39/39 ,  A61P31/22 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K9/19 ,  A61K39/25 ,  A61K39/39 ,  A61P31/22 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/6056 ,  C07K2319/30 ,  C12N2710/16722 ,  C12N2710/16734

Abstract: The present disclosure discloses a recombinant varicella-zoster virus (VZV) vaccine, including a fusion protein formed by an amino acid sequence of an extracellular domain of a recombinant glycoprotein gE of a live attenuated VZV strain (OKA strain) gene and an Fc fragment of human immunoglobulin. The present disclosure further provides preparation and use of the fusion protein, a corresponding recombinant gene, a eukaryotic expression vector, etc. The fusion protein of the present disclosure has prominent immunogenicity and can induce the high-level expression of neutralizing antibodies in serum.

公开(公告)号：US20240165236A1

公开(公告)日：2024-05-23

申请号：US18341194

申请日：2023-06-26

Applicant: Allergan, Inc.

Inventor： Terrence J. Hunt

IPC: A61K47/10 ,  A61K9/00 ,  A61K9/19 ,  A61K38/48 ,  A61K47/26 ,  A61K47/32

CPC classification number: A61K47/10 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/4893 ,  A61K47/26 ,  A61K47/32

Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.